Exagen (XGN) Competitors $6.74 -0.24 (-3.37%) As of 07/3/2025 02:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. FLGT, PSNL, CSTL, INNV, FTRE, EHAB, AUNA, TALK, SBC, and CELCShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Fulgent Genetics (FLGT), Personalis (PSNL), Castle Biosciences (CSTL), InnovAge (INNV), Fortrea (FTRE), Enhabit (EHAB), Auna (AUNA), Talkspace (TALK), SBC Medical Group (SBC), and Celcuity (CELC). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors Fulgent Genetics Personalis Castle Biosciences InnovAge Fortrea Enhabit Auna Talkspace SBC Medical Group Celcuity Exagen (NASDAQ:XGN) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends. Do analysts prefer XGN or FLGT? Exagen presently has a consensus price target of $7.50, suggesting a potential upside of 11.36%. Fulgent Genetics has a consensus price target of $24.00, suggesting a potential upside of 19.64%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Fulgent Genetics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation & earnings, XGN or FLGT? Exagen has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$56.72M2.53-$15.11M-$0.84-8.02Fulgent Genetics$283.47M2.15-$42.71M-$1.33-15.08 Which has more volatility and risk, XGN or FLGT? Exagen has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Is XGN or FLGT more profitable? Fulgent Genetics has a net margin of -13.94% compared to Exagen's net margin of -27.34%. Fulgent Genetics' return on equity of -2.19% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-27.34% -133.69% -34.87% Fulgent Genetics -13.94%-2.19%-2.02% Does the media refer more to XGN or FLGT? In the previous week, Fulgent Genetics had 1 more articles in the media than Exagen. MarketBeat recorded 2 mentions for Fulgent Genetics and 1 mentions for Exagen. Fulgent Genetics' average media sentiment score of 0.23 beat Exagen's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulgent Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of XGN or FLGT? 75.3% of Exagen shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryExagen and Fulgent Genetics tied by winning 8 of the 16 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.46M$10.19B$5.49B$9.01BDividend YieldN/A2.09%5.38%4.09%P/E Ratio-8.0216.7427.4220.26Price / Sales2.5329.14407.97121.21Price / CashN/A22.8436.6357.47Price / Book12.473.668.085.67Net Income-$15.11M$235.40M$3.16B$248.47M7 Day Performance-3.79%2.15%2.81%3.29%1 Month Performance-8.62%3.00%3.68%5.19%1 Year Performance272.10%-10.21%35.29%21.35% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen3.6671 of 5 stars$6.74-3.4%$7.50+11.4%+272.1%$143.46M$56.72M-8.02220FLGTFulgent Genetics3.3348 of 5 stars$19.33-1.0%$24.00+24.2%+0.7%$594.56M$283.47M-14.531,313Positive NewsPSNLPersonalis3.3691 of 5 stars$6.21-3.3%$7.67+23.5%+534.9%$567.05M$84.61M-4.81400News CoverageCSTLCastle Biosciences3.0796 of 5 stars$18.85+1.8%$37.00+96.3%-4.5%$534.72M$332.07M-99.21540INNVInnovAge0.6823 of 5 stars$3.97+2.1%$5.00+25.9%-12.5%$525.20M$763.85M-17.262,350News CoverageFTREFortrea4.0349 of 5 stars$5.10-4.1%$15.00+194.1%-77.7%$481.46M$2.70B-0.5815,500EHABEnhabit2.1274 of 5 stars$9.27flat$8.50-8.3%-12.1%$469.41M$1.03B-3.3510,700AUNAAuna3.5925 of 5 stars$6.24+0.5%$10.70+71.5%-20.6%$459.62M$4.35B10.7614,842High Trading VolumeTALKTalkspace3.9529 of 5 stars$2.76+3.0%$4.50+63.0%+28.4%$448.40M$187.59M138.07500Positive NewsSBCSBC Medical GroupN/A$4.34+0.7%N/AN/A$446.56M$197.94M0.00N/ACELCCelcuity2.1778 of 5 stars$11.45-1.3%$30.80+169.0%-15.5%$439.25MN/A-3.7840Analyst Forecast Related Companies and Tools Related Companies FLGT Alternatives PSNL Alternatives CSTL Alternatives INNV Alternatives FTRE Alternatives EHAB Alternatives AUNA Alternatives TALK Alternatives SBC Alternatives CELC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
